ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

REPL Replimune Group Inc

6.95
0.39 (5.95%)
04 5월(5) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Replimune Group Inc REPL 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
0.39 5.95% 6.95 09:00:00
개장가 저가 고가 종가 전일 종가
6.80 6.605 7.08 6.95 6.56
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
08/04/202406:00GLOBEInterim Results from the ARTACUS Clinical Trial of RP1..
04/04/202421:00GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
26/03/202420:30GLOBEReplimune Announces Appointment of Sushil Patel to CEO and..
06/03/202422:00GLOBEReplimune to Present at the American Association for Cancer..
05/03/202422:00GLOBEReplimune to Present at Three Upcoming Investor Conferences
14/02/202421:21EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/02/202422:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/02/202422:05EDGAR2Form 8-K - Current report
08/02/202422:00GLOBEReplimune Reports Fiscal Third Quarter 2024 Financial..
16/01/202418:06PRNUSDISCO Pharmaceuticals launches as the surfaceome company..
16/01/202417:59PRNUSDISCO Pharmaceuticals launches as the surfaceome company..
08/01/202422:00EDGAR2Form 8-K - Current report
28/12/202322:00GLOBEReplimune to Present at the 42nd Annual J.P. Morgan..
27/12/202307:15EDGAR2Form 8-K - Current report
05/12/202321:19EDGAR2Form 8-K - Current report
05/12/202321:00GLOBEReplimune Shares Initial Primary Analysis Results from..
18/11/202310:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/11/202310:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202323:10GLOBEReplimune Presents Updated Data on RP2 in Uveal Melanoma..
08/11/202307:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202322:15EDGAR2Form 8-K - Current report
07/11/202322:00GLOBEReplimune Reports Fiscal Second Quarter 2024 Financial..
04/11/202308:30GLOBEReplimune Presents Updated Interim Results from the ARTACUS..
21/09/202309:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/09/202309:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
20/09/202305:01GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
19/09/202321:15EDGAR2Form 8-K - Current report
19/09/202321:00GLOBEReplimune Announces Appointment of Emily Hill as Chief..
14/09/202310:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/09/202322:17EDGAR2Form 8-K - Current report
25/08/202309:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/08/202309:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/08/202322:04EDGAR2Form 8-K - Current report
03/08/202321:45EDGAR2Form S-3ASR - Automatic shelf registration statement of..
03/08/202321:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/08/202321:09EDGAR2Form 8-K - Current report
03/08/202321:00GLOBEReplimune Reports Fiscal First Quarter 2024 Financial..
01/08/202321:00GLOBEReplimune to Present at Two Upcoming Investor Conferences
01/08/202305:01BWReplimune and Incyte Enter into Clinical Trial Collaboration..
27/07/202309:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
27/07/202306:08EDGAR2Form ARS - Annual Report to Security Holders
27/07/202306:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
27/07/202306:02EDGAR2Form DEF 14A - Other definitive proxy statements
20/07/202321:56EDGAR2Form 8-K - Current report
20/07/202321:00GLOBEReplimune Announces Sander Slootweg will Depart from its..
12/07/202310:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/07/202305:27EDGAR2Form 144 - Report of proposed sale of securities
06/06/202323:00GLOBEReplimune Presents Initial RP1 Data from the ARTACUS..
05/06/202321:00GLOBEReplimune Appoints Veleka R. Peeples-Dyer to its Board of..
04/06/202303:15GLOBEReplimune Presents RP1 Data from the IGNYTE anti-PD1 Failed..

최근 히스토리

Delayed Upgrade Clock